[go: up one dir, main page]

BR0116922A - Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila - Google Patents

Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila

Info

Publication number
BR0116922A
BR0116922A BR0116922-0A BR0116922A BR0116922A BR 0116922 A BR0116922 A BR 0116922A BR 0116922 A BR0116922 A BR 0116922A BR 0116922 A BR0116922 A BR 0116922A
Authority
BR
Brazil
Prior art keywords
dimethyl sulfoxide
low toxicity
aqueous composition
free
parenteral aqueous
Prior art date
Application number
BR0116922-0A
Other languages
English (en)
Inventor
Srikanth Pai
Sangeeta Rivankar
Original Assignee
Bharat Serums & Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums & Vaccines Ltd filed Critical Bharat Serums & Vaccines Ltd
Publication of BR0116922A publication Critical patent/BR0116922A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

"PROCESSO PARA A FABRICAçãO DE UMA COMPOSIçãO AQUOSA PARENTERAL ISENTA DE SULFóXIDO DE DIMETILA COM BAIXA TOXICIDADE; E COMPOSIçãO AQUOSA PARENTERAL DE BAIXA TOXICIDADE ISENTA DE SULFóXIDO DE DIMETILA". Descreve-se composições aquosas parenterais de baixa toxicidade, isentas de sulfóxido de dimetila, contendo anfotericina B. As composições consistem essencialmente, além da anfotericina B, de fosfolipídeos e cloreto de sódio. As composições são esterilizadas em autoclave. Os processos para fabricar estas composições, sem o uso de solventes para dissolver a anfotericina B, foram descritos. As composições são indicadas no tratamento de infecções fúngicas invasivas.
BR0116922-0A 2001-03-01 2001-03-16 Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila BR0116922A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN217MU2001 IN188924B (pt) 2001-03-01 2001-03-01
PCT/IN2001/000040 WO2002069983A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition

Publications (1)

Publication Number Publication Date
BR0116922A true BR0116922A (pt) 2004-04-27

Family

ID=11097223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116922-0A BR0116922A (pt) 2001-03-01 2001-03-16 Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila

Country Status (23)

Country Link
US (1) US20040137049A1 (pt)
EP (1) EP1368041B1 (pt)
JP (1) JP2004523566A (pt)
KR (1) KR100810067B1 (pt)
CN (1) CN1255114C (pt)
AT (1) ATE274913T1 (pt)
AU (1) AU2001250643B2 (pt)
BG (1) BG108188A (pt)
BR (1) BR0116922A (pt)
CA (1) CA2438847A1 (pt)
CZ (1) CZ20032264A3 (pt)
DE (1) DE60105322T2 (pt)
DK (1) DK1368041T3 (pt)
EA (1) EA006241B1 (pt)
ES (1) ES2227172T3 (pt)
IN (1) IN188924B (pt)
MX (1) MXPA03007777A (pt)
NZ (1) NZ528281A (pt)
PT (1) PT1368041E (pt)
SK (1) SK10742003A3 (pt)
WO (1) WO2002069983A1 (pt)
YU (1) YU75403A (pt)
ZA (1) ZA200307307B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN100418536C (zh) * 2005-04-06 2008-09-17 河南省眼科研究所 一种用于眼科的抗真菌药物组合物
CN101453982B (zh) 2006-05-30 2011-05-04 精达制药公司 两件式内部通道渗透递送系统流动调节器
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
KR101629521B1 (ko) * 2010-03-16 2016-06-13 우석대학교 산학협력단 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
WO2013142184A1 (en) * 2012-03-19 2013-09-26 Yale University Antimicrobial compositions and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
EP3222324B1 (en) 2016-03-23 2020-05-13 Wayne State University Valproate as a topical anti-fungal treatment
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CN108344811A (zh) * 2017-01-24 2018-07-31 北京泰德制药股份有限公司 一种注射用脂质体中有机溶剂残留的检测方法
CN108309955B (zh) * 2018-04-27 2020-06-02 武昌理工学院 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Also Published As

Publication number Publication date
DE60105322D1 (de) 2004-10-07
MXPA03007777A (es) 2003-12-08
EP1368041A1 (en) 2003-12-10
WO2002069983A1 (en) 2002-09-12
ZA200307307B (en) 2004-04-20
ES2227172T3 (es) 2005-04-01
YU75403A (sh) 2006-05-25
EA006241B1 (ru) 2005-10-27
KR20040018337A (ko) 2004-03-03
CZ20032264A3 (cs) 2003-12-17
EA200300948A1 (ru) 2004-04-29
CA2438847A1 (en) 2002-09-12
BG108188A (bg) 2004-09-30
JP2004523566A (ja) 2004-08-05
PT1368041E (pt) 2005-01-31
EP1368041B1 (en) 2004-09-01
CN1505519A (zh) 2004-06-16
AU2001250643B2 (en) 2007-03-22
US20040137049A1 (en) 2004-07-15
ATE274913T1 (de) 2004-09-15
DK1368041T3 (da) 2005-01-17
NZ528281A (en) 2006-11-30
CN1255114C (zh) 2006-05-10
IN188924B (pt) 2002-11-23
KR100810067B1 (ko) 2008-03-05
SK10742003A3 (sk) 2004-01-08
DE60105322T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
BR0116922A (pt) Processo para a fabricação de uma composição aquosa parenteral isenta de sulfóxido de dimetila com baixa toxicidade; e composição aquosa parenteral de baixa toxicidade isenta de sulfóxido de dimetila
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA200000594A1 (ru) Новые макролиды
PT1075837E (pt) Processo de preparacao de formulacoes aquosas para utilizacao oftalmicas
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
CY1106704T1 (el) Αλογονουχος συνθεση, η μεθοδος παρασκευης της και οι χρησεις της
UY30030A1 (es) Derivados sustituidos de la 8-piracin-2-il-1,2,4,4a-tetrahidro-2´h, 6h-espiro (1,4-oxacin(4,3-a)quinolin-5,5´-pirimidin)-2´, 4´, 6´ (1´h, 3´h)-tiona, composiciones y aplicaciones
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
CY1113175T1 (el) Ενωση σουλφοναμιδης και εφαρμογη αυτης
NO20005497L (no) Heterocykliske derivater som inhiberer faktor Xa
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
BRPI0417175A (pt) composições, método para produzir essas composições, solução que as compreende e métodos para utilizar as mesmas
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
WO2003090744A8 (en) Antibacterial compositions comprising metal phthalocyanine analogues
BRPI0215189B8 (pt) composição viscoelástica aquosa, estéril, para uso em procedimentos cirúrgicos oftálmicos
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
UY27311A1 (es) Agentes antibacterianos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/715, A61K 47/14, A61K 9/127, A61P 31/00

Ipc: A61K 31/715 (2010.01), A61K 47/14 (2010.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time